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California at San Francisco, San Francisco, CA 94158, UVibrio vulniﬁcus is an opportunistic human pathogen that causes severe infections in susceptible
individuals. While the components of the Escherichia coli phosphoenolpyruvate: sugar phospho-
transferase system (PTS) have been shown to regulate numerous targets, little such information is
available for the V. vulniﬁcus PTS. Here we show that enzyme IIAGlc of the PTS regulates the peptidase
activity of a mammalian insulysin homolog in V. vulniﬁcus. While interaction of IIAGlc with the
insulysin homolog is independent of the phosphorylation state of IIAGlc, only unphosphorylated
IIAGlc activates the insulysin homolog. Taken together, our results suggest that the V. vulniﬁcus
insulysin-IIAGlc complex plays a role in survival in the host by sensing glucose.
Structured summary:
MINT-8045996:
IIA glu (uniprotkb:Q7MBY2) binds (MI:0407) to vIDE (uniprotkb:Q7MIS6) by pull down (MI:0096)
MINT-8045817, MINT-8045967:
IIA glu (uniprotkb:Q7MBY2) physically interacts (MI:0915) with vIDE (uniprotkb:Q7MIS6) by pull down
(MI:0096)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction responsible for the majority of human infections [1]. Biotype 2Vibrio vulniﬁcus is a Gram-negative bacterium that is found in
estuarine waters and frequently contaminates seafood. Strains of
V. vulniﬁcus are classiﬁed into three biotypes based on their bio-
chemical characteristics and those belonging to biotype 1 arechemical Societies. Published by E
phosphoenolpyruvate:sugar
S; HPr, histidine-containing
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hromatography; vIDE, Vibrio
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atrix-assisted laser desorp-
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f Biophysics and Chemical
l University, Seoul 151-742,
d Immunology, University of
SA.strains are primary eel pathogens, while the biotype 3 appears to
be emerged by recombination between biotypes 1 and 2 genomes
and causes human wound infection [2]. Primary septicemia is the
most lethal infection caused by V. vulniﬁcus, with an average mor-
tality rate exceeding 50%. Predisposing factors for severe V. vulnif-
icus infection include chronic liver disease, elevated serum iron
levels, low gastric acid, immunosuppression, and diabetes [3–5].
Most septic patients die of fulminant septicemia within 48 h after
infection, implying that V. vulniﬁcus cells subvert host innate im-
mune responses upon infection.
The bacterial phosphoenolpyruvate (PEP):sugar phosphotrans-
ferase system (PTS) participates in several physiological processes,
in addition to its role in coupling phosphorylation to translocation
of numerous sugars across the cytoplasmic membrane [6]. The PTS
is composed of two general proteins, enzyme I (EI) and histidine-
containing phosphocarrier protein (HPr), and a set of sugar-speciﬁc
proteins collectively known as enzymes II. EI and HPr mediate
phosphoryl transfer from PEP to enzyme II, which ﬁnally phos-
phorylates PTS sugar substrates during uptake. Therefore, the ratio
of the phosphorylated forms of the PTS components increases inlsevier B.V. All rights reserved.
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the PTS have been most extensively studied in Escherichia coli, and
these roles include regulation of chemotaxis by EI [6], regulation of
glycogen phosphorylase by HPr [7], and sequestration of the global
repressor Mlc by glucose-speciﬁc enzyme IICB to induce expres-
sion of the PTS proteins in the presence of PTS sugars [8–11]. In
addition, glucose-speciﬁc enzyme IIA (IIAGlc) plays multiple roles
such as regulation of adenylyl cyclase, inducer exclusion of non-
PTS sugars to preferentially consume glucose, inhibition of glycerol
kinase activity, and regulation of fermentation/respiration switch
protein [6,12,13].
Although the PTS has never been documented in V. vulniﬁcus,
we postulated that it might play important roles in V. vulniﬁcus
physiology. We therefore set out to isolate a protein(s) that inter-
acts with and is regulated by IIAGlc in V. vulniﬁcus because all of the
regulatory roles of the PTS reported to date are mediated through
the direct interaction of the PTS components with their target pro-
teins, and because IIAGlc is the key regulatory component among
Gram-negative bacterial PTSs [6,12–14].
2. Materials and methods
2.1. Strains, plasmids and culture media
Bacterial strains and plasmids used in this study are listed in
Table 1. V. vulniﬁcus strains were cultured in Luria-Bertani medium
containing 2.5% NaCl (LBS) and all E. coli strains except BL21(DE3)
derivatives were grown in M9 medium supplemented with 2%
casamino acids and 1% glycerol. BL21 (DE3) strains were grown
in LB medium.
To construct a V. vulniﬁcus strain deleted for the mammalian
insulysin homolog (hereafter referred as vIDE, which stands for
V. vulniﬁcus insulin-degrading enzyme), the region covering the
gene (hereafter referred as ideV) equivalent to the locus
VV1_1977 in the sequenced V. vulniﬁcus CMCP6 genome was ampli-
ﬁed from the chromosomal DNA of V. vulniﬁcus MO6-24/O [15] by
PCR with primers 50-AAACGCCACGGGGGCCCGCGCAGCATCCTG-30
(an engineered ApaI site underlined) and 50-TTGCACTACTTGAG-
CTCAGTAGAGAAAATG-30 (an engineered SacI site underlined). ThisTable 1
Bacterial strains and plasmids used in this study.
Strains or plasmids Genotypes and/or descriptions
Bacterial strains
V. vulniﬁcus strains
MO6-24/O Wild-type, Biotype 1, Clinical isolate
MO6-24/O DideV MO6-24/O DideV::Kmr
E. coli strains
GI698 F k lacIq lacPL8 ampC::Ptrp cI
GI698Dpts GI698 D(ptsH, ptsI, crr), Kmr
BL21(DE3) pLysS
SM10kpir thi-1 thr leu tonA lacY supE recA::Rp4-2-Tc
Plasmids
pRE1 Expression vector under control of kPL prom
pRE-His-Tag pRE1-based expression vector for N-termina
pRH-vIDE ideV cloned into pRE-His-Tag for expression
pRE-vIDE ideV cloned into pRE1 for erexpression of vI
pRH-vCrr V. vulniﬁcus crr encoding IIAGlc cloned into p
pRH-PtsI E. coli ptsI encoding EI cloned into pRE-His-
pCR-BluntII-TOPO-hIDE Cloning vector of human insulysin (hIDE), K
pET3a Expression vector for N-terminal His6-tagge
pET-hIDE hIDE-encoding gene cloned into pET3a
pGEM-T Easy Cloning vector for PCR product, Apr
pDM4 Suicide vector for homologous recombinatio
pDM4-vIDE pDM4-based suicide vector for replacement
Apr, ampicilin resistance; Kmr, kanamycin resistance; Cmr, chloramphenicol resistance.fragment was ligated into pGEM-T Easy (Promega). The internal
region of the ideV ORF was digested with AﬂII and XhoI and re-
placed with the neo gene. This plasmid containing the kanamycin
cassette within the ideV ORF was digested with ApaI and SacI
and cloned into the pDM4 vector [16] to make pDM4-vIDE. The
V. vulniﬁcus strain deleted for ideV was generated by homologous
recombination using E. coli SM10 kpir harboring pDM4-vIDE as a
conjugal donor to V. vulniﬁcus MO6-24/O [17].
To construct expression vectors for the vIDE, the coding region
was ampliﬁed from the chromosomal DNA of V. vulniﬁcusMO6-24/
O using PCR with the primers 50-TTTCGGAGACGCCATATGCACTT-
AAGTCCA-30 (an engineered NdeI site underlined) and 50-
TTGCTTCTTTGTCGACTGCTTGTTTCTTTG-30 (an engineered SalI site
underlined). After digestion, the NdeI–SalI fragment was inserted
into the corresponding sites of pRE-His-Tag [18] to make pRH-vIDE
for overexpression of the vIDE with an N-terminal His6 and into
pRE1 [19] to make pRE-vIDE for overexpression of the vIDE
without His tags. To construct the expression vector pRH-vCrr for
V. vulniﬁcus IIAGlc with His6 at the N-terminus (His-IIAGlc), the crr
gene (equivalent to the locus VV1_0212 in the CMCP6 strain) was
ampliﬁed using PCR with the primers 50-ACCTTAGGAGCAT-
GACCATATGGGTCTGTT-30 (NdeI site underlined) and 50-GGCAG-
TGCAATTGGATCCCTATCTTAGGTT-30 (BamHI site underlined). The
PCR product was digested with NdeI and BamHI and cloned into
pRE-His-Tag. The overexpression vector pRH-PtsI for E. coli EI with
an N-terminal His6 tag was constructed by moving the NdeI–
BamHI fragment including the ORF for EI from pPR6 [20] into the
corresponding sites of pRE-His-Tag.
To construct the expression vector for human insulysin, endoge-
nous NdeI and BamHI sites in the plasmid containing the full-length
human insulysin cDNA (ImaGenes) were removed by PCR using si-
lent mutagenic primers. The DNA fragment extending from the
42nd ATG codon to the stop codon and containing a His6 tag at the
N-terminus was ampliﬁed using PCR with primers: forward primer,
50-CTTACAGCCATATGCACCACCACCACCACCACAATAATCCAGCCATC
AAGAGAATAGGAAATCAC (NdeI site underlined); and reverse pri-
mer, 50-GCATGGGGGATCCTCAGAGTTTTGCAGCCATG (BamHI site
underlined). After digestion, theNdeI–BamHI fragmentwas inserted
into the corresponding sites of pET3a (Novagen).Source or reference
[37]
This study
[21]
[21]
Novagen
::Mu kpir;Kmr [38]
oter, Apr [19]
l His6-tagged proteins, Apr [18]
of His6-tagged vIDE, Apr This study
DE, Apr This study
RE-His-Tag, Apr This study
Tag,, Apr This study
mr ImaGenes
d proteins under control of N7 promoter, Apr Novagen
This study
Promega
n into V. vulniﬁcus chromosome, Cmr [16]
of ideV with neo, Cmr and Kmr This study
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All the proteins with N-terminal His6 tags used in this study
were overexpressed in E. coli GI698Dpts strains [21] for pRE1-
based vectors or BL21 (DE3) strains for pET vectors, and puriﬁed
using TALON™ metal afﬁnity resin (Clontech) according to the
manufacturer’s instructions. The proteins were eluted with
200 mM imidazole and further puriﬁed by gel ﬁltration chroma-
tography (Superose 12, 1.6  50 cm; GE Healthcare) in buffer A
(20 mM HEPES–KOH, pH 8.0, containing 100 mM NaCl). The vIDE
without a His6 tag was overexpressed in E. coli strain GI698Dpts
harboring pRE-vIDE. Cells were harvested 20 h after induction with
1 mM tryptophan, disrupted by sonication and centrifuged at
100,000g for 40 min at 4 C. The vIDE was puriﬁed from the
supernatant by DEAE-Sepharose (Sigma), HiLoad 16/60 Super-
dex75 prepgrade (GE Healthcare), and Mono Q 10/100 (GE Health-
care) chromatography according to the method described for
puriﬁcation of E. coli FrsA [13]. E. coli EI and HPr were puriﬁed as
described previously [9]. Protein concentration was determined
by bicinchoninic acid protein assay (Pierce).
2.3. Identiﬁcation of a protein interacting with IIAGlc
V. vulniﬁcus MO6-24/O cells grown at 30 C overnight in LBS
(500 ml) were harvested, washed and resuspended in 10 ml of buf-
fer A. Cells were disrupted by sonication and centrifuged at
100,000g for 40 min at 4 C. The supernatant (2 ml) was mixed
with 2 mg of either IIAGlc or His–IIAGlc, and this mixture was incu-
bated with 500 ll of TALON™ metal-afﬁnity resin at 4 C for
30 min. After incubation, the resin was harvested and washed with
1 ml of buffer A three times, and the proteins bound to the column
were eluted with 500 ll of buffer A containing 200 mM imidazole.
Aliquots of the eluted protein samples were analyzed by SDS–PAGE
using a 4–20% gradient gel and staining with Coomassie blue. The
protein band that speciﬁcally bound to His-IIAGlc was excised from
the gel and in-gel digestion and peptide mapping of tryptic digests
were carried out using the Voyager-DE STR MALDI-TOF mass spec-
trometer (Applied Biosystems Inc.) as previously described [22,23].
To test the speciﬁcity of the interaction between IIAGlc and the
vIDE, the E. coli GI698Dpts strain [21] harboring pRE-vIDE was
grown in 50 ml of M9 medium, induced for protein expression
with 1 mM tryptophan, harvested, washed, and resuspended in
Buffer A. After puriﬁcation, the vIDE (20 lg) was mixed with vari-
ous concentrations of puriﬁed His-IIAGlc (or His-tagged E. coli EI as
a control) and 50 ll of TALON™ metal afﬁnity resin in a total vol-
ume of 500 ll. After the mixture was loaded into a column, the col-
umn was washed and the proteins bound to the column were
eluted with 50 ll of 2 SDS sample buffer and analyzed by 14%
SDS–PAGE. Proteins were stained with Coomassie Brilliant Blue R
and scanned with an LAS-3000 (Fujiﬁlm) for densitometric
analysis.
To test the phosphorylation dependence of the interaction be-
tween IIAGlc and the vIDE, vIDE (20 lg) was incubated with EI
(3 lg), HPr (4.5 lg) and His-IIAGlc (10 lg) in a total volume of
500 ll of buffer A containing 2 mM DTT and 2 mM MgCl2 in the
presence of 1 mM glucose (to ensure complete dephosphorylation
of His-IIAGlc) or PEP (to ensure complete phosphorylation of His-
IIAGlc) and subjected to pull-down assays as described above.
2.4. Measurement of peptidase activity
Puriﬁed vIDE (1 lM) was incubated with human insulin (pur-
chased from Sigma-Aldrich) in 100 mM Tris–HCl (pH 7.5) in the
presence or absence of IIAGlc (2 lM) at 30 C. The reaction was ter-
minated by adding SDS-PAGE loading buffer or 1/10 volume of 5.5%
triﬂuoroacetic acid (Fluka). The degradation of insulin was mea-sured by SDS–PAGE followed by staining with Coomassie Brilliant
Blue R or injecting digests through high performance liquid chro-
matography (HPLC). For the HPLC analyses, samples were applied
to C18 Hypersil™ Gold (Thermo) which had been washed with
0.1% triﬂuoroacetic acid in acetonitrile (B) and equilibrated with
0.1% triﬂuoroacetic acid in water (A). The insulin peak was resolved
using a linear gradient of 0–60% B over 50 min, followed by 60–
100% B over 10 min. A ﬂow rate of 1.0 ml/min was used, and insu-
lin was detected with a UV detector set at 215 nm.
2.5. Comparison of survival rate and virulence of V. vulniﬁcus strains
in mice
Wild-type V. vulniﬁcus MO6-24/O and its otherwise isogenic
vIDE deletion mutant strains were grown in LBS to OD600 = 0.6.
After wash with phosphate-buffered saline (PBS), the bacterial cells
were resuspended in PBS at a concentration of 3  106 cells/ml.
Equal numbers of the two strains (3  105 cells per each strain)
were intraperitoneally injected into speciﬁc pathogen-free seven-
week-old female ICR mice. The livers and spleens of the infected
mice were removed 2 h after injection and homogenized in 5 ml
of PBS. The homogenates were serially diluted in PBS and aliquots
were spread onto the thiosulfate citrate bile salts sucrose (TCBS)
agar plates in the presence or absence of kanamycin (250 lg/ml).
The fraction of mutant cells was estimated by enumerating kana-
mycin-resistant colonies.
Seven-week-old female ICR mice were subcutaneously injected
with iron dextran (80 lg/g body weight). After incubation for 1 h,
100 ll of freshly grown bacterial suspension in PBS (containing
about 1.5  104 of wild-type or vIDE deletion mutant V. vulniﬁcus
cells) was injected intraperitoneally into each mouse and the num-
ber of dead mice was determined.
All animal procedures were previously approved by the Insti-
tute of Laboratory Animal Resources at Seoul National University.
3. Results
3.1. An insulysin homolog interacts with IIAGlc in V. vulniﬁcus
To search for a protein(s) interacting with IIAGlc, V. vulniﬁcus
crude extract was mixed with His-IIAGlc and subjected to a pull-
down assay [22]. Through several independent trials, we could ﬁnd
a protein band migrating with an apparent molecular mass of
100 kDa that always co-eluted with His-IIAGlc (Fig. 1A). In-gel
digestion followed by MALDI-TOF analysis [22] revealed that the
protein corresponds to the hypothetical M16 Zn-metallopeptidase
family protein vIDE. The vIDE protein has greatest sequence simi-
larity with mammalian insulysins, also known as insulinase or
insulin-degrading enzyme, apart from its similarity to its homologs
in species closely related to the Vibrionaceae family of bacteria
(Supplementary Table S1).
To conﬁrm the speciﬁc interaction of vIDE with IIAGlc, vIDE was
mixed with His-IIAGlc and subjected to a pull-down assay (Fig. 1B).
In one set of reactions, glucose was added, along with E. coli EI and
HPr, to maintain IIAGlc in dephosphorylated form (the reaction
mixtures labeled Glc). In another set of reaction mixtures, PEP, EI,
and HPr were included to maintain IIAGlc in phosphorylated form
(the reaction mixtures labeled PEP). Phosphorylation of IIAGlc was
conﬁrmed by its mobility shift in a SDS–PAGE gel [24]. As expected
from the Zn-binding nature of the M16 metallopeptidase family
proteins, a small fraction of the puriﬁed vIDE bound to the metal
afﬁnity resin even without His-IIAGlc (Figs. 1B and 2A). However,
the amount of the vIDE protein bound to the resin was signiﬁcantly
greater when His-IIAGlc was bound to the afﬁnity resin. Although
most regulatory interactions between IIAGlc and its target proteins
depend strictly on the phosphorylation state of IIAGlc in E. coli
Fig. 1. Speciﬁc interaction between IIAGlc and vIDE in V. vulniﬁcus. (A) Pull-down
assay to search for protein factor(s) interacting with IIAGlc in V. vulniﬁcus. Crude
extract of V. vulniﬁcus MO6-24/O cells was mixed with 2 mg of either puriﬁed
His–IIAGlc (lane +) or IIAGlc (lane –), and processed as described in Section 2. Aliquots
of the eluted protein samples were analyzed by 4–20% gradient SDS–PAGE followed
by staining with Coomassie blue. In-gel digestion followed by MALDI-TOF analysis
revealed that the protein band speciﬁcally bound to His–IIAGlc corresponded to vIDE
encoded by ideV (marked with an arrow). Lane M, molecular mass markers (Koma
Biotech, Inc.). (B) Interaction of IIAGlc with vIDE is independent of its phosphory-
lation state. vIDE (20 lg) was incubated with EI (3 lg) and HPr (4.5 lg) in the
presence or absence of His-IIAGlc (10 lg). Mixtures designated Glc and PEP were
supplemented with 1 mM glucose and PEP to ensure complete dephosphorylation
and phosphorylation of the added IIAGlc, respectively. The mixtures were then
subjected to a pull-down assay using the TALONTM resin. P-IIAGlc stands for the
phosphorylated form of His-IIAGlc.
Fig. 2. Kinetics of the interaction between IIAGlc and vIDE. (A) vIDE (20 lg) was
incubated with increasing amounts of His-EI or His-IIAGlc (0, 15, 30, 60, and 120 lg)
in a total volume of 500 ll and subjected to a pull-down assay. (B) After the SDS–
polyacrylamide gel was scanned, the amount of vIDE speciﬁcally bound to IIAGlc
(bound to the column containing His-IIAGlc minus bound to the control column
containing His-EI) was calculated and the concentration of free IIAGlc was obtained
by subtracting the amount of bound vIDE from the total IIAGlc for Scatchard
analysis.
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tion state (Fig. 1B).
The concentration dependence of the interaction between IIAGlc
and vIDE was studied to measure the afﬁnity of the interaction.
While the amount of the vIDE protein bound to the column was
independent of the amount of His-EI pre-bound to the afﬁnity re-
sin, it increased as the amount of His-IIAGlc added to the column in-
creased, conﬁrming that vIDE speciﬁcally interacts with IIAGlc
(Fig. 2A). The KD was calculated to be about 2.0 lM assuming a
1:1 interaction using Scatchard analysis (Fig. 2B). Noteworthily,this binding afﬁnity is in the similar range as reported for other
regulatory interactions involving IIAGlc in E. coli [12,25,26].
3.2. vIDE activity is dependent on dephosphorylated IIAGlc
A BLAST search revealed that this peptidase is widespread in a
variety of organisms including animals, plants, fungi, and protists
as well as bacteria (Supplementary Table S1). Amino acid sequence
comparison showed that vIDE has an HXXEH active-site motif
present in all known members of the Zn-metalloendopeptidase
M16 superfamily (Supplementary Fig. S1) [27]. We therefore mea-
sured the insulinolytic activity of vIDE and analyzed the effect of
IIAGlc on vIDE activity using reverse-phase HPLC [28] (Fig. 3A). Be-
cause insulysins in other organisms do not require any other pro-
tein factors for activity [27], it was surprising that the puriﬁed
vIDE alone did not show any insulinolytic activity. However, when
we added IIAGlc to the reaction mixture together with vIDE, the
substrate insulin was completely degraded. IIAGlc alone did not
show any insulinolytic activity, implying that the apparent activa-
tion of vIDE by IIAGlc does not reﬂect contamination with proteases
during the preparation of IIAGlc. It was previously shown that hu-
man insulysin is inhibited by the thiol-modifying agent N-ethyl-
maleimide (NEM) and, to a less extent, by the metal chelator
ethylenediaminetetraacetic acid (EDTA) while the insulin-degrad-
ing activity of E. coli protease III is little affected by NEM but almost
completely inhibited by EDTA [29]. Interestingly, the insulin-
degrading activity of vIDE was sensitive to NEM as well as EDTA
Fig. 3. Insulin-degrading activity of vIDE. (A) Absolute requirement of IIAGlc for the insulinolytic activity of vIDE. Human insulin (Sigma–Aldrich) (designated by an arrow)
was incubated with vIDE and/or IIAGlc for 30 min and injected to a C18 Hypersil™ Gold reverse-phase HPLC column after terminating the reaction by adding triﬂuoroacetic
acid. (B) Effect of various chemicals on the insulin-degrading activity of the vIDE-IIAGlc complex. vIDE (1 lM) was mixed with IIAGlc (2 lM) in the presence or absence of
chemicals (1 mM) and the insulin-degrading reactions were initiated by adding insulin (35 lM). After 30 min, the reactions were stopped by adding the SDS–PAGE loading
buffer and analyzed by 4–20% gradient SDS–PAGE and staining with Coomassie blue. Lane 1, insulin; lane 2, insulin + IIAGlc; lane 3, insulin + vIDE; lane 4,
insulin + IIAGlc + vIDE; lane 5, insulin + IIAGlc + vIDE + EDTA; lane 6, insulin + IIAGlc + vIDE + EGTA; lane 7, insulin + IIAGlc + vIDE + NEM; lane 8, insulin + IIAGlc + vIDE + TPEN;
lane M, molecular mass markers (Koma Biotech, Inc.).
Fig. 4. Phosphorylation state-dependent activation of vIDE by IIAGlc. (A) Phosphor-
ylation of IIAGlc abolishes its stimulatory activity. Insulin (40 lM) was incubated
with EI (2 lM), HPr (5 lM), and IIAGlc (2 lM) in the presence of 1 mM PEP or
glucose. At the indicated time points after addition of vIDE (1 lM), aliquots were
mixed with 2 SDS–PAGE loading buffer and resolved on a 20% SDS–PAGE gel. (B)
Speciﬁc activity of vIDE in the presence of various concentrations of IIAGlc. The
degradation of insulin by vIDE (1 lM) was measured in the presence of IIAGlc at the
indicated concentrations. Reactions were incubated for 10 min and stopped by
adding 1/10 volume of 5.5% triﬂuoroacetic acid (TFA) and the amounts of remaining
insulin were quantiﬁed by HPLC.
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with mammalian insulysins. The zinc chelator N,N,N0,N0-tetra-
kis(2-pyridylmethyl)ethylenediamine (TPEN), but not the calcium
chelator ethylene glycol tetraacetic acid (EGTA), also inhibited
vIDE, indicating that Zn is indispensable for the peptidase activity
of vIDE.
Frequently, the phosphorylation state of a regulatory protein
modulates the activity of its interacting partners. For example, only
the phosphorylated form of E. coli IIAGlc can activate adenylyl cy-
clase, while their interaction is independent of the phosphorylation
state of IIAGlc [12]. To conﬁrmwhether IIAGlc is required for activity
of vIDE, and to test whether this activation depends on the phos-
phorylation state of IIAGlc, the reaction mixture containing vIDE,
EI, HPr and IIAGlc was pre-incubated with either PEP or glucose be-
fore the reaction was initiated by the addition of insulin. The assay
mixture containing phosphorylated IIAGlc did not show any detect-
able stimulation of insulinolytic activity, while the activity of vIDE
was noticeably stimulated by dephosphorylated IIAGlc (Fig. 4A).
This result indicates that only dephosphorylated IIAGlc can activate
vIDE, although both forms of IIAGlc interact with this protein
(Fig. 1B).
The speciﬁc activity of vIDE increased hyperbolically with
increasing concentration of IIAGlc (Fig. 4B). Maximal speciﬁc
activity of vIDE against insulin was 7.82 lmoles/min per lmoles
of vIDE and half-maximal activation could be obtained in the pres-
ence of 1.13 lM IIAGlc, which is comparable to the KD of the protein
complex (Fig. 2B). Then, we compared the speciﬁc activity of vIDE
with that of recombinant human insulysin which could degrade
insulin without any cofactor. As expected, the insulinolytic activity
of human insulysin was little affected by IIAGlc. Intriguingly, vIDE
showed about four times higher activity than human insulysin in
the presence of IIAGlc (Table 2).
It was previously reported that mammalian insulysins can also
degrade other peptides such as amylin, b-amyloid protein and
b-endorphin [30,31]. We found that vIDE can also degrade other
peptides such as b-amyloid protein and b-endorphin in addition
to insulin in the presence of IIAGlc (Fig. 5). These data indicate that
vIDE needs to make a complex with IIAGlc to catalyze its peptidase
Table 2
Comparison of insulinolytic activities between vIDE and human insulysin. vIDE and
recombinant human insulysin (1 lM each) in the presence or absence of IIAGlc
(20 lM) was incubated with human insulin (100 lM, Sigma–Aldrich) in 100 mM
Tris–HCl (pH 7.5) at 30 C (n = 3). Reactions were terminated by adding 1/10 volume
of 5.5% triﬂuoroacetic acid and the degradation of insulin was measured through
HPLC.
Speciﬁc activity (lmoles of insulin/min/lmoles of enzyme)
vIDE Human insulysin
 IIAGlc No activity 2.22 ± 0.21
+ IIAGlc 7.82 ± 0.34 2.18 ± 0.13
Fig. 5. Hydrolysis of b-endorphin and b-amyloid by vIDE. (A) vIDE was mixed with
b-endorphin and its hydrolytic activity was measured after incubation for 30 min:
Lane 1, b-endorphin alone; lane 2, b-endorphin + vIDE; lane 3, b-endorphin + vIDE +
IIAGlc. (B) vIDE was mixed with b-amyloid in the presence (+) or absence (–) of IIAGlc
and incubated for the indicated time periods to measure its hydrolytic activity.
Samples were run on a 20% SDS–PAGE gel and stained with Coomassie blue.
Fig. 6. Effect of vIDE on virulence of V. vulniﬁcus. The iron dextran treated seven-
week-old female ICR mice were intraperitoneally injected with 1.5  104 cells of
wild-type V. vulniﬁcus (circles) or DideV mutant (squares) to test their virulence
(P < 0.0001; n = 11 each).
Table 3
Effect of vIDE on survival of V. vulniﬁcus in host. Equal numbers of wild-type and
DideV cells (3  105 per each strain) were intraperitoneally injected into female ICR
mice (n = 3). The homogenates of livers and spleens extracted 2 h after injection were
serially diluted in PBS and colony-forming units (CFU) were determined on the TCBS
agar plates. The fraction of the mutant cells was estimated by enumerating
kanamycin-resistant colonies.
MO6-24/O DideV
Spleen 35,920 ± 1245 1350 ± 495
Liver 3300 ± 141 Not detected
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with IIAGlc has similar biochemical characteristics with mamma-
lian insulysins.
3.3. vIDE affects survival and virulence of V. vulniﬁcus in mice
To address the role of vIDE in V. vulniﬁcus, we compared growth
of an ideV deletion mutant with that of its parental strain in a set of
20 96-well microplates containing different nutrients and inhibi-
tors by employing Phenotype MicroarrayTM (Biolog Co.). Out of
nearly 2000 cellular phenotypes examined, only 3 parameters
were observed as meaningfully different in the ideV mutant in
two independent experiments (see Supplementary Fig. S2). When
we compared growth of the two strains in ﬂasks, however, none
of these phenotypes could be veriﬁed as signiﬁcantly different in
the mutant. Furthermore, we could ﬁnd no additional phenotypes
resulting from the ideV mutation with respect to colony morphol-
ogy and growth at different temperatures in different media
regardless of whether glucose was present.
Then, we assumed that vIDE might be necessary for infection of
this pathogenic bacteria to animal hosts. Therefore, we sought to
determine whether vIDE plays a role in virulence in a mouse mod-
el. Seven-week-old ICR mice were infected with 1.5  104 cells of
the wild-type or DideV V. vulniﬁcus strains. This number of cells
was chosen because it is about 10-fold higher than the wild-type
LD50 determined in pre-test [32]. All the mice injected with wild-
type V. vulniﬁcus cells died within 15 h, whereas those injected
with DideV cells survived well (Fig. 6). From this result, we as-
sumed that deletion of the ideV gene might inﬂuence its survival
efﬁciency in the infected mice. Therefore, survival of this pathogen
in mice was measured. Two hours after co-infection of equal num-bers of wild-type and the DideV mutant, the viable numbers of
each bacterial strain were determined in livers and spleens of the
infected mice. The competitive index of DideV mutant compared
to wild-type was less than 0.04 in both spleen and liver (Table
3). These results demonstrate that vIDE is important for survival
of this pathogen during host infection.
4. Discussion
Bacteria have the capacity to efﬁciently adapt to environmental
changes by re-directing metabolic pathways. The carbohydrate PTS
plays an important role in re-directing carbohydrate metabolisms
by monitoring a certain carbon source from the environment [6].
In addition to its role in sugar transport, the carbohydrate PTS
has many secondary functions. It switches on and off the utiliza-
tion of a large number of carbon sources in response to the avail-
ability of glucose, primarily via controlling the state of
phosphorylation of IIAGlc. In this study, we show for the ﬁrst time
that IIAGlc regulates the activity of a protease homologous to mam-
malian insulysin in V. vulniﬁcus by direct interaction. While the
speciﬁc interaction of IIAGlc with the insulysin homolog is indepen-
dent of the phosphorylation state of IIAGlc, the peptidase activity of
the insulysin homolog is strictly dependent on the unphosphory-
lated form of IIAGlc (Figs. 1B and 4A). In addition to the insulin, it
is able to degrade other mammalian insulysin substrates such as
b-endorphin and b-amyloid (Fig. 5). Taken together, our results
suggest that the vIDE-IIAGlc complex exhibits similar biochemical
properties to the mammalian insulysins and could act by sensing
glucose in the environment.
Estuarine seawaters, which are natural habitats for V. vulniﬁcus,
are usually oligotrophic and thus lack glucose. Upon infection, the
bacterial cells are exposed to the relatively eutrophic milieu. One
possible way for a bacterial pathogen to recognize the host
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glucose. A variety of regulatory functions exerted by the bacterial
PTS depend on the phosphorylation states of the involved compo-
nents, and the cellular fraction of the unphosphorylated forms of
the PTS components increases in the presence of a sugar substrate
of the PTS [6]. Therefore, it could be predicted that the PTS sugar
glucose in the host blood serum would inﬂuence the physiological
state and thus survival of the pathogens exhibiting tropism for
blood vessels and spreading intravascularly such as V. vulniﬁcus
[33]. In this study, we supported this prediction by showing atten-
uated virulence and host colonization of a mutant deﬁcient in vIDE
whose activity is strictly dependent on the unphosphorylated form
of IIAGlc of the PTS (Fig. 6 and Table 3). Recently, relationship be-
tween carbohydrate utilization and virulence has been studied in
several human pathogenic bacteria such as Listeria monocytogenes,
Bacillus anthracis and group A Streptococcus [34–36]. In these spe-
cies, the change of environmental carbohydrates acts as a signal
to control their virulence gene expression through the regulation
of a virulence transcription factor. In case of V. vulniﬁcus, however,
we hypothesize that the PTS senses glucose in host to activate vIDE
which plays a role in survival during infection.
Although insulin is a central regulator of glucose homeostasis in
mammals and we provide several lines of evidences showing that
the vIDE-IIAGlc complex has similar biochemical properties with
mammalian insulysins (Figs. 3B, 5, and S1 and Table S1), it still
remains to be clariﬁed how vIDE regulates survival of V. vulniﬁcus
cells in mice. vIDE and IIAGlc were found exclusively in the
cytoplasm and, compared with the DideV strain, wild-type
V. vulniﬁcus showed no signiﬁcant difference in the insulin-degrad-
ing activity unless cells were disrupted (data not shown). There-
fore, more experiments are needed to identify the real substrates
of vIDE that might regulate adaptation of this pathogen to the host
environment.
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